

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (canceled).

at least one anti-cancer agent; and

3. **(previously presented)** The polymer drug conjugate according to Claim 2, wherein said α is succinoylated from 30% to 40mol%.

4. **(previously presented)** The polymer drug conjugate according to Claim 3, wherein said dextrin is succinoylated from 32% to 36mol%.

5. **(previously presented)** The polymer drug conjugate according to Claim 4, wherein said dextrin is succinoylated to about 34mol%.

6. (currently amended) The polymer drug conjugate according to Claim 1, wherein the percentage of α -1-6 linkages in the dextran is less than 10%.

7. **(previously presented)** The polymer drug conjugate according to Claim 6, wherein the percentage of α 1-6 linkages in the dextran is less than 5%.

8. **(currently amended)** The polymer drug conjugate according to Claim 1, wherein the molecular weight of the dextran is in an average molecular weight range 1000-200000.

9. **(previously presented)** The polymer drug conjugate according to Claim 8, wherein the molecular weight of the dextrin is in an average molecular weight range 2000-55000.

10. **(currently amended)** The polymer drug conjugate according to any of Claim 1 2, wherein the dextrin contains more than 15% of polymers of DP greater than 12.

11. **(previously presented)** The polymer drug conjugate according to Claim 10, wherein the dextrin contains more than 50% of polymers of DP greater than 12.

12. **(currently amended)** A polymer drug conjugate according to Claims 1 2, wherein said anti cancer agent is selected from the group consisting of: cyclophosphamide; melphalan; carmusline; methotrexate, 5-fluorouracil; cytarabine; mercaptopurine; anthracyclines; daunorubicin, doxorubicin; epirubicin; vinca alkaloids; vinblastin; vincristine; dactinomycin; mitomycin C; taxol; L-asparaginase; G-CSF; cisplatin; and, optionally, carboplatin.

13. **(currently amended)** A pharmaceutical composition, comprising the polymer drug conjugate according to Claim 1 2 and a pharmaceutically acceptable diluent, excipient or carrier.

14. **(canceled)**

15. **(canceled)**

16. **(currently amended)** A polymer drug conjugate comprising:
at least one biologically active agent; and
a dextrin polymer, wherein said dextrin polymer is modified by succinoylation by at least ~~20~~ 30mol% characterised in that the stability of the polymer drug conjugate is enhanced.

17. **(previously presented)** The polymer conjugate according to Claim 16, wherein said agent is an imaging agent.

18. **(previously presented)** The polymer conjugate according to Claim 17, wherein the imaging agent is tyrosinamide.

19. **(previously presented)** The polymer conjugate according to Claim 16, wherein said agent is a diagnostic agent.

20. **(previously presented)** The polymer conjugate according to Claim 16 wherein said agent is a targeting agent.

21. **(previously presented)** The polymer conjugate according to Claim 20 wherein the targeting agent is biotin.

22. **(currently amended)** A method for treating a cancer in an animal subject, comprising administering to the animal a pharmaceutically effective amount of the polymer drug conjugate according to Claim 1 + 2, thereby treating the cancer in the subject.

23. **(previously presented)** The method according to Claim 22 wherein said animal is human.